[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569135":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":25,"id":58,"slug":25,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Affiliated Hospital of Nantong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"sulfentanil group","ACTIVE_COMPARATOR","Participants in the active comparator group will receive sulfentanil for PCIA.",[13],"Procedure: patient controlled intravenous analgesia(PCIA)",{"label":15,"type":16,"description":17,"interventionNames":18},"oxycodone group","EXPERIMENTAL","Participants in the experimental group will receive oxycodone for PCIA.",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","patient controlled intravenous analgesia(PCIA)","Patients will receive sulfentanil for PCIA.",[9],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"Patients will receive oxycodone for PCIA.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Siyuan Liu, PhD","CONTACT","+86-85050301","tdfylsy@ntu.edu.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Affiliated hospital of Nantong University","RECRUITING","Nantong","Jiangsu","226001","China",{"type":44,"coordinates":45},"Point",[46,47],120.87472,32.03028,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":25,"email":53},"Wei Shi","0513-85052297","jsrdwbb@126.com",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Siyuan Liu","Principal Investigator","100569135",false,"NCT06690307","Oxycodone Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy","The Efficacy and Safety of Oxycodone in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy","Oxycodone","Inclusion Criteria:\n\n* selective laparoscopic hysterectomy\n* general anesthesia\n* ASA classification I - III\n* aged 18 - 65 years\n\nExclusion Criteria:\n\n* allergy to oxycodone or any other drugs will be used in the study\n* preoperative opioids medication\n* opioids abuse\n* hepatic or renal dysfunction\n* cardiovascular or pulmonary dysfunction\n* lack of full civil capacity or refuse to participate","FEMALE","18 Years","65 Years",{"count":69,"type":70},64,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","This study is designed to evaluate the efficacy and safety of hydrocodone in patient-controlled intravenous analgesia (PCIA) during gynecological laparoscopy, thus to explore suitable PCIA scheme to optimize postoperative pain management for patients undergoing gynecological laparoscopic surgeries.",[76],"Laparoscopic Hysterectomy",[78,79,80],"oxycodone","patient-controlled intravenous analgesia","laparoscopic hysterectomy","2024-12-02",{"date":83,"type":84},"2024-12-04","ACTUAL",{"date":86,"type":84},"2024-12-03",{"date":88,"type":70},"2026-07-31",{"name":5,"class":6},1]